Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 84 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: metformin extended release Clear all
Completed Phase 3 Interventional Results available

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

NCT00643851
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

NCT00778141
View directory record Official record
Conditions
Healthy
Interventions
metformin HC1 750 mg extended-release tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions

NCT00865852
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 3, 2026, 6:52 PM EDT
Active, not recruiting Not applicable Interventional

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

NCT05040087
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
Other
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
40 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851095
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

NCT01441869
View directory record Official record
Conditions
Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Interventions
Onglyza (saxagliptin), Diabex, 5-mg saxagliptin/1000 mg metformin, 5-mg saxagliptin/500 mg metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Oct 3, 2026, 6:52 PM EDT
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 3, 2026, 6:52 PM EDT
Recruiting Phase 2Phase 3 Interventional

Impact of Metformin on Immuno-virologic Parameters in HIV

NCT04500678
View directory record Official record
Conditions
HIV/AIDS
Interventions
Metformin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
40 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 2Phase 3 Interventional

Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study

NCT04409795
View directory record Official record
Conditions
Type 1 Diabetes, Monogenic Diabetes
Interventions
Metformin Extended Release Oral Tablet, Sitagliptin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
Up to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 4 Interventional Results available

Ranolazine and Microvascular Angina by PET in the Emergency Department

NCT02052011
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

NCT01845077
View directory record Official record
Conditions
Healthy
Interventions
2x500 mg Metformin (Glumetza), 5 mg Linagliptin/1000 mg Metformin FDC, 5 mg Linagliptin (Tradjenta), 3x500 mg Metformin (Glumetza), 2 x 500 mg Metformin (Glumetza), 5 mg Linagliptin/1000mg Metformin FDC, 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 3, 2026, 6:52 PM EDT
Terminated Phase 3 Interventional Results available

REMAP Trial for Optimizing Surgical Outcomes at UPMC

NCT03861767
View directory record Official record
Conditions
Aging
Interventions
Metformin ER, Placebo
Drug
Lead sponsor
Matthew Neal MD
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 1 Interventional

Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)

NCT02086526
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02073227
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg, CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 3, 2026, 6:52 PM EDT
Withdrawn Phase 4 Interventional

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer

NCT04741204
View directory record Official record
Conditions
Breast Cancer Stage, Insulin Resistance, Racial Bias
Interventions
Metformin Extended Release Oral Tablet
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 3, 2026, 6:52 PM EDT
Terminated Phase 4 Interventional Results available

Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)

NCT02500147
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 3, 2026, 6:52 PM EDT
Terminated Phase 1 Interventional

An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

NCT01816659
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Metformin ER
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 3, 2026, 6:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea

NCT04530747
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Metformin + PAP, Placebo oral capsule + PAP
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
35 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 3, 2026, 6:52 PM EDT
Not listed Phase 2 Interventional

Metformin for HIV Inflammation

NCT02383563
View directory record Official record
Conditions
HIV, Coronary Artery Disease
Interventions
metformin extended release
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

NCT01234649
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions
Metformin XR plus placebo, Metformin XR plus liraglutide
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 3, 2026, 6:52 PM EDT
Completed Phase 2 Interventional Results available

Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus

NCT01447927
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hines, Illinois • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 3, 2026, 6:52 PM EDT
Not listed Phase 1 Interventional

Metformin and Esomeprazole For Preterm Pre-eclampsia

NCT05232994
View directory record Official record
Conditions
Preeclampsia Severe, Preeclampsia Second Trimester, Preterm Birth Complication
Interventions
Esomeprazole 20mg
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 3, 2026, 6:52 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Oral Metformin for Treatment of ABCA4 Retinopathy

NCT04545736
View directory record Official record
Conditions
ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal Degeneration
Interventions
Metformin hydrochloride
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 3, 2026, 6:52 PM EDT